Netherlands· NL-d9f84246e22f
Cinqaero 10 mg/ml concentraat voor oplossing voor infusie
A reslizumab product containing reslizumab, registered in Netherlands by Teva B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Reslizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DX08 (reslizumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Reslizumab · ATC R03DX08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- RESLIZUMAB
- Manufacturer
- Teva B.V.
- Country
- Netherlands (NL)
- ATC code
- R03DX08
- ATC class
- Reslizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/16/1125
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- SwitzerlandCinqaero 100 mg/10 mL, Konzentrat zur Herstellung einer InfusionslösungTeva Pharma AG
- BelgiumCinqaero 10 mg/mlTeva
- FinlandCINQAEROOrifarm Oy
- United KingdomCinqaero 100mg/10ml concentrate for solution for infusion vialsTeva UK Ltd
- SwedenCINQAERO 10 mg/ml Koncentrat till infusionsvätska, lösningTeva B.V.
- United StatesCINQAIRTeva Respiratory, LLC
- IrelandCINQAERO 10 mg/mL concentrate for solution for infusionTeva B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Cinqaero
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/741fcede-f3eb-474b-b7a6-c26da851fb62 GET /v1/drugs/741fcede-f3eb-474b-b7a6-c26da851fb62?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/cinqaero-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Reslizumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp117642",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMACETAAT 3-WATER (E 262)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"RESLIZUMAB"
],
"leaflet_url": null,
"authorised_at": "2016/08/16",
"procedure_number": "EMEA/H/C/003912",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/16/1125",
"additional_monitoring": "N"
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.